Drug Trial Radar · NCT04666610
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Jul 29, 2021
Primary completion
Jul 7, 2026
Study completion Jul 7, 2026
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Dec 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Conditions
- Childhood Absence Epilepsy
- Juvenile Absence Epilepsy
Interventions
BrivaracetamDrug
* Pharmaceutical form: Oral solution * Route of administration: Oral use Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.
PlaceboOther
Subjects will receive placebo at pre-specified time-points to maintain the blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who met the criteria for absence seizure freedom within 4 days prior to or during the 24-hour ambulatory electroencephalogram (EEG) at Day 14Time frame: Day 14
Locations
35 sites in 7 countries. Site status is shown where the registry gives one.
N01269 115
Birmingham, Alabama
N01269 105
Orange, California
N01269 116
Denver, Colorado
N01269 111
Miami, Florida
N01269 101
Tampa, Florida
N01269 104
Winter Park, Florida
N01269 110
Augusta, Georgia
N01269 100
New Brunswick, New Jersey
N01269 109
Winston-Salem, North Carolina
N01269 106
Philadelphia, Pennsylvania
N01269 400
Tbilisi, Georgia
N01269 401
Tbilisi, Georgia
N01269 402
Tbilisi, Georgia
N01269 403
Tbilisi, Georgia
N01269 405
Tbilisi, Georgia
N01269 323
Messina, Italy
N01269 321
Milan, Italy
N01269 324
Milan, Italy
N01269 320
Pavia, Italy
N01269 322
Roma, Italy
N01269 325
Roma, Italy
N01269 326
Verona, Italy
N01269 562
Bucharest, Romania
N01269 563
Bucharest, Romania
N01269 560
Iași, Romania
N01269 561
Timişoara, Judeţ Timiş, Romania
N01269 632
Bardejov, Slovakia
N01269 630
Dubnica nad Váhom, Slovakia
N01269 631
Nové Zámky, Slovakia
N01269 354
Terrassa, Spain
N01269 600
Dnipro, Ukraine
N01269 601
Dnipro, Ukraine
N01269 604
Kharkiv, Ukraine
N01269 607
Uzhhorod, Ukraine
N01269 602
Vinnytsia, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.